DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Altice
Frederick L
FL
Springer
Sandra A
SA
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D024882:Drug Resistance, Viral; D000068679:Emtricitabine; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage; D010349:Patient Compliance; D011744:Pyrimidinones; D012367:RNA, Viral / Q000032:analysis; D016032:Randomized Controlled Trials as Topic; D018119:Stavudine / Q000008:administration & dosage; D000068698:Tenofovir; D016896:Treatment Outcome; D055815:Young Adult
D019380:Anti-HIV Agents; D063065:Organophosphonates; D011744:Pyrimidinones; D012367:RNA, Viral; D003841:Deoxycytidine; D061466:Lopinavir; D000068698:Tenofovir; D018119:Stavudine; D000068679:Emtricitabine; D000225:Adenine